CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2003-07-18): EU approves label change for Pegasys/Copegus used to treat hepatitis C

Regulatory

EU approves label change for Pegasys/Copegus used to treat hepatitis C

Last Updated: 2003-07-18 12:07:16 -0400 (Reuters Health)

ZURICH (Reuters) - The European Commission has approved a new approach to administering Roche's treatment for hepatitis C, the Swiss healthcare group said on Friday.

The change means physicians can vary the dosages of ribavirin given in combination with Pegasys (pegylated interferon alfa-2a), depending on the kind of the virus that patients have, Roche said.

Patients with the hard-to-treat type 1 virus would get 12 months of therapy with standard doses of Copegus--Roche's brand of ribavirin--while those with types 2 and 3 would get six months of treatment at lower levels of Copegus.

Roche said the change would allow patients to stop treatment as soon as warranted.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.